TABLE 2.
Antimicrobial activity of imipenem-relebactam and comparators against Enterobacterales during the SUPERIOR and STEP surveillance studies broken down by countries
| All enterobacterales (no. tested)/antimicrobials | EUCAST |
CLSI |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sb |
I |
R |
S |
I |
R |
||||||||||
| MIC50 | MIC90 | Range | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | |
| All Enterobacterales in Spain (n = 359, SUPERIOR) | |||||||||||||||
| CZAa | 0.12 | 0.5 | ≤0.03 to >64 | 356 | 99.2 | 3 | 0.8 | 356 | 99.2 | 3 | 0.8 | ||||
| CTZa | 0.25 | 8 | 0.12 to >32 | 314 | 87.5 | 45 | 12.5 | 314 | 87.5 | 5 | 1.4 | 40 | 11.1 | ||
| IMRa | 0.12 | 0.5 | 0.06 to >64 | 351 | 97.8 | 8 | 2.2 | 337 | 93.9 | 14 | 3.9 | 8 | 2.2 | ||
| IMI | 0.12 | 1 | 0.06 to 64 | 351 | 97.8 | 2 | 0.6 | 6 | 1.7 | 334 | 93.0 | 17 | 4.7 | 8 | 2.2 |
| All Enterobacterales in Portugal (n = 388, STEP) | |||||||||||||||
| CZA | 0.12 | 0.5 | ≤0.03 to >64 | 387 | 99.7 | 1 | 0.3 | 387 | 99.7 | 1 | 0.3 | ||||
| CTZ | 0.25 | 8 | 0.12 to >32 | 335 | 86.3 | 53 | 13.7 | 335 | 86.3 | 9 | 2.3 | 44 | 11.3 | ||
| IMR | 0.12 | 0.5 | 0.06 to 64 | 386 | 99.5 | 2 | 0.5 | 383 | 98.7 | 3 | 0.8 | 2 | 0.5 | ||
| IMI | 0.12 | 1 | 0.06 to 64 | 367 | 94.6 | 5 | 1.3 | 16 | 4.1 | 358 | 92.3 | 9 | 2.3 | 21 | 5.4 |
a
Imipenem-relebactam (IMR), ceftazidime-avibactam (CZA), and ceftolozane-tazobactam (CTZ) were tested with a fixed concentration of 4 mg/liter of relebactam, avibactam and tazobactam.
b
S/I/R, susceptible, standard dose/susceptible, increased exposure/resistant, by EUCAST; susceptible/intermediate/resistant, by CLSI.